Tagged parkinsons-drug

GB Sciences Signs Licensing Deal With EndoPure Life Sciences for 5% Gross Sales Royalty & Sponsorship of First-in-Human Trial for Their Cannabinoid-Based Parkinson’s Drug
Press Release

GB Sciences Signs Licensing Deal With EndoPure Life Sciences for 5% Gross Sales Royalty & Sponsorship of First-in-Human Trial for Their Cannabinoid-Based Parkinson’s Drug

 As a part of their Exclusive Licensing Deal, EndoPure Life Sciences will finance and sponsor first-in-human clinical trials, which help to advance GB Sciences’ cannabinoid-based products globally. Read More
GB Sciences Signs Letter of Intent for a License to Develop and Market Their Cannabinoid-Based Parkinson’s Formulation With Endopure Life Sciences
Press Release

GB Sciences Signs Letter of Intent for a License to Develop and Market Their Cannabinoid-Based Parkinson’s Formulation With Endopure Life Sciences

 GB Sciences’ Licensing Deal with Endopure Life Sciences will also include Rights to Develop and Market GB Sciences’ Cannabinoid-based Treatments for a Suite of Neurological Disorders Read More
Gb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with kathy ireland®
Press Release

Gb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with kathy ireland®

 Tune in this Sunday, Dec. 17, at 5:30 p.m. ET on the Fox Business Network to learn about Gb Sciences’ cannabinoid-based medicine for the treatment of Parkinson’s disease. Read More
Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge
Press Release

Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge

 The Parkinson's disease market is expected to grow to $12.8 billion by 2028. Read More